# Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis

> **NCT03086486** · PHASE3 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 181 (actual)

## Conditions studied

- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, MDR
- Tuberculosis
- Extensively Drug-Resistant Tuberculosis
- Pre-XDR-TB
- XDR-TB

## Interventions

- **DRUG:** Pretomanid
- **DRUG:** Linezolid
- **DRUG:** Bedaquiline
- **DRUG:** Placebo Linezolid

## Key facts

- **NCT ID:** NCT03086486
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-21
- **Primary completion:** 2021-02-15
- **Final completion:** 2022-02-08
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03086486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03086486, "Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03086486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*